|
FR901228A
(fr)
|
1943-01-16 |
1945-07-20 |
Deutsche Edelstahlwerke Ag |
Système d'aimant à entrefer annulaire
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4943533A
(en)
|
1984-03-01 |
1990-07-24 |
The Regents Of The University Of California |
Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
|
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
US6303121B1
(en)
|
1992-07-30 |
2001-10-16 |
Advanced Research And Technology |
Method of using human receptor protein 4-1BB
|
|
US6355476B1
(en)
|
1988-11-07 |
2002-03-12 |
Advanced Research And Technologyinc |
Nucleic acid encoding MIP-1α Lymphokine
|
|
US6362325B1
(en)
|
1988-11-07 |
2002-03-26 |
Advanced Research And Technology Institute, Inc. |
Murine 4-1BB gene
|
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
|
US5399346A
(en)
|
1989-06-14 |
1995-03-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Gene therapy
|
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
|
US5061620A
(en)
|
1990-03-30 |
1991-10-29 |
Systemix, Inc. |
Human hematopoietic stem cell
|
|
DE69233482T2
(de)
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
|
US5199942A
(en)
|
1991-06-07 |
1993-04-06 |
Immunex Corporation |
Method for improving autologous transplantation
|
|
WO1992022653A1
(en)
|
1991-06-14 |
1992-12-23 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
US5851795A
(en)
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
|
ES2136092T3
(es)
|
1991-09-23 |
1999-11-16 |
Medical Res Council |
Procedimientos para la produccion de anticuerpos humanizados.
|
|
AU2764792A
(en)
|
1991-10-04 |
1993-05-03 |
Iit Research Institute |
Conversion of plastic waste to useful oils
|
|
GB9125768D0
(en)
|
1991-12-04 |
1992-02-05 |
Hale Geoffrey |
Therapeutic method
|
|
ES2202310T3
(es)
|
1991-12-13 |
2004-04-01 |
Xoma Corporation |
Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos.
|
|
US6005079A
(en)
|
1992-08-21 |
1999-12-21 |
Vrije Universiteit Brussels |
Immunoglobulins devoid of light chains
|
|
DE69330523T4
(de)
|
1992-08-21 |
2012-08-23 |
Vrije Universiteit Brussel |
Immunoglobuline ohne leichte ketten
|
|
US5350674A
(en)
|
1992-09-04 |
1994-09-27 |
Becton, Dickinson And Company |
Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
|
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
|
NZ258392A
(en)
|
1992-11-13 |
1997-09-22 |
Idec Pharma Corp |
Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona
|
|
ES2191702T3
(es)
|
1994-03-17 |
2003-09-16 |
Merck Patent Gmbh |
Fv monocatenarios anti-egfr y anticuerpos anti-egfr.
|
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
|
US5773292A
(en)
|
1995-06-05 |
1998-06-30 |
Cornell University |
Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood
|
|
US7060808B1
(en)
|
1995-06-07 |
2006-06-13 |
Imclone Systems Incorporated |
Humanized anti-EGF receptor monoclonal antibody
|
|
US5811097A
(en)
|
1995-07-25 |
1998-09-22 |
The Regents Of The University Of California |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US6051227A
(en)
|
1995-07-25 |
2000-04-18 |
The Regents Of The University Of California, Office Of Technology Transfer |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US6136311A
(en)
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
|
US6107090A
(en)
|
1996-05-06 |
2000-08-22 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
|
|
EP0826696B1
(de)
|
1996-09-03 |
2002-05-29 |
GSF-Forschungszentrum für Umwelt und Gesundheit GmbH |
Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
|
|
EP0948353A1
(en)
|
1996-10-11 |
1999-10-13 |
Bristol-Myers Squibb Company |
Methods and compositions for immunomodulation
|
|
ATE461282T1
(de)
*
|
1997-10-27 |
2010-04-15 |
Bac Ip Bv |
Multivalente antigenbindende proteine
|
|
AU3596599A
(en)
|
1998-01-26 |
1999-08-09 |
Unilever Plc |
Method for producing antibody fragments
|
|
HUP9900956A2
(hu)
|
1998-04-09 |
2002-04-29 |
Aventis Pharma Deutschland Gmbh. |
Egyláncú, több antigéntkötőhely kialakítására képes molekulák, előállításuk és alkalmazásuk
|
|
US6682736B1
(en)
|
1998-12-23 |
2004-01-27 |
Abgenix, Inc. |
Human monoclonal antibodies to CTLA-4
|
|
EP1144616B2
(en)
|
1999-01-19 |
2009-01-14 |
Unilever Plc |
Method for producing antibody fragments
|
|
ES2539411T3
(es)
|
1999-08-23 |
2015-06-30 |
Dana-Farber Cancer Institute, Inc. |
PD-1, receptor para la B7-4 y su utilización
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
CN1371416B
(zh)
|
1999-08-24 |
2012-10-10 |
梅达里克斯公司 |
人ctla-4抗体及其应用
|
|
ATE240744T1
(de)
|
1999-10-28 |
2003-06-15 |
Hofbauer Reinhold |
Verwendung von csf-1-inhibitoren
|
|
US6326193B1
(en)
|
1999-11-05 |
2001-12-04 |
Cambria Biosciences, Llc |
Insect control agent
|
|
US20060228364A1
(en)
|
1999-12-24 |
2006-10-12 |
Genentech, Inc. |
Serum albumin binding peptides for tumor targeting
|
|
WO2001054732A1
(en)
|
2000-01-27 |
2001-08-02 |
Genetics Institute, Llc. |
Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
|
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
ES2302726T3
(es)
|
2000-02-24 |
2008-08-01 |
Invitrogen Corporation |
Estimulacion y concentracion simultanea de celulas.
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
AU2001263114A1
(en)
|
2000-05-12 |
2001-11-26 |
Amgen Inc |
Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
|
|
US20030190598A1
(en)
|
2000-05-26 |
2003-10-09 |
Jasmid Tanha |
Single-domain antigen-binding antibody fragments derived from llama antibodies
|
|
WO2001096584A2
(en)
|
2000-06-12 |
2001-12-20 |
Akkadix Corporation |
Materials and methods for the control of nematodes
|
|
DE60140461D1
(de)
|
2000-09-11 |
2009-12-24 |
Genzyme Corp |
Muc1 extrazelluläre domäne und zusammensetzungen für krebsbehandlung, und davon abgeleitete verfahren
|
|
GB0100621D0
(en)
|
2001-01-10 |
2001-02-21 |
Vernalis Res Ltd |
Chemical compounds VI
|
|
CN1294148C
(zh)
|
2001-04-11 |
2007-01-10 |
中国科学院遗传与发育生物学研究所 |
环状单链三特异抗体
|
|
GB0110029D0
(en)
|
2001-04-24 |
2001-06-13 |
Grosveld Frank |
Transgenic animal
|
|
CN1195779C
(zh)
|
2001-05-24 |
2005-04-06 |
中国科学院遗传与发育生物学研究所 |
抗人卵巢癌抗人cd3双特异性抗体
|
|
US7666414B2
(en)
|
2001-06-01 |
2010-02-23 |
Cornell Research Foundation, Inc. |
Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
|
|
JP4298498B2
(ja)
|
2001-06-13 |
2009-07-22 |
ゲンマブ エー／エス |
上皮成長因子受容体（ｅｇｆｒ）に対するヒトモノクローナル抗体
|
|
US7595378B2
(en)
|
2001-06-13 |
2009-09-29 |
Genmab A/S |
Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
|
|
WO2003025020A1
(en)
|
2001-09-13 |
2003-03-27 |
Institute For Antibodies Co., Ltd. |
Method of constructing camel antibody library
|
|
US20050215472A1
(en)
|
2001-10-23 |
2005-09-29 |
Psma Development Company, Llc |
PSMA formulations and uses thereof
|
|
AU2002356844C1
(en)
|
2001-10-23 |
2010-03-04 |
Amgen Fremont Inc. |
PSMA antibodies and protein multimers
|
|
JP2005289809A
(ja)
|
2001-10-24 |
2005-10-20 |
Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) |
突然変異重鎖抗体
|
|
US7745140B2
(en)
|
2002-01-03 |
2010-06-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
|
|
AU2003224604B2
(en)
|
2002-01-28 |
2007-06-14 |
Medarex, Inc. |
Human monoclonal antibodies to prostate specific membrane antigen (PSMA)
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
NZ586071A
(en)
|
2002-05-02 |
2012-02-24 |
Wyeth Corp |
Calicheamicin derivative-carrier conjugates comprising a CD22 antibody
|
|
US9321832B2
(en)
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
|
EP2366718A3
(en)
*
|
2002-06-28 |
2012-05-02 |
Domantis Limited |
Ligand
|
|
PL375144A1
(en)
|
2002-07-30 |
2005-11-28 |
Bristol-Myers Squibb Company |
Humanized antibodies against human 4-1bb
|
|
ATE540978T1
(de)
|
2002-10-17 |
2012-01-15 |
Genmab As |
Humane monoklonale antikörper gegen cd20
|
|
EP1561114B1
(en)
|
2002-11-07 |
2008-05-07 |
Erasmus Universiteit Rotterdam |
Fret probes and methods for detecting interacting molecules
|
|
SI1578446T1
(sl)
|
2002-11-07 |
2015-07-31 |
Immunogen, Inc. |
Protitelesa proti-cd33 in metoda za zdravljenje akutne mieloidne levkemije z uporabo istega
|
|
WO2004041867A2
(en)
|
2002-11-08 |
2004-05-21 |
Ablynx N.V. |
Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders
|
|
ES2466716T3
(es)
|
2002-11-08 |
2014-06-11 |
Ablynx N.V. |
Anticuerpos de un solo dominio estabilizados
|
|
US9320792B2
(en)
|
2002-11-08 |
2016-04-26 |
Ablynx N.V. |
Pulmonary administration of immunoglobulin single variable domains and constructs thereof
|
|
NZ540194A
(en)
|
2002-11-08 |
2008-07-31 |
Ablynx Nv |
Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
|
|
GB0228210D0
(en)
|
2002-12-03 |
2003-01-08 |
Babraham Inst |
Single chain antibodies
|
|
BRPI0316779B1
(pt)
|
2002-12-16 |
2020-04-28 |
Genentech Inc |
anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados
|
|
ES2367430T3
(es)
|
2002-12-23 |
2011-11-03 |
Wyeth Llc |
Anticuerpos contra pd-1 y sus usos.
|
|
WO2004106380A2
(en)
|
2003-05-31 |
2004-12-09 |
Micromet Ag |
Human-anti-human cd3 binding molecules
|
|
RU2005141512A
(ru)
*
|
2003-05-31 |
2007-07-20 |
Микромет Аг (De) |
Фармацевтические композиции, включающие биспецифические анти-cd3, анти-cd19 конструкции антител для лечения расстройств, связанных с b-клетками
|
|
EP1638510B1
(en)
|
2003-07-01 |
2015-09-02 |
Immunomedics, Inc. |
Multivalent carriers of bi-specific antibodies
|
|
EP1639013B1
(en)
|
2003-07-02 |
2012-09-12 |
Innate Pharma |
Pan-kir2dl NK-receptor antibodies and their use in diagnostic and therapy
|
|
KR20060038461A
(ko)
|
2003-07-24 |
2006-05-03 |
이나뜨 파르마 |
Ｎｋ 세포 강화 화합물을 사용하여 치료용 항체의 효율을높이는 방법 및 조성물
|
|
ES2458636T3
(es)
|
2003-08-18 |
2014-05-06 |
Medimmune, Llc |
Humanización de anticuerpos
|
|
AU2004280333A1
(en)
|
2003-08-22 |
2005-04-21 |
Medimmune, Llc |
Humanization of antibodies
|
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
|
SI1673398T1
(sl)
|
2003-10-16 |
2011-05-31 |
Micromet Ag |
Multispecifiäśne deimunizirajoäśe cd3 povezovalne molekule
|
|
CN100376599C
(zh)
*
|
2004-04-01 |
2008-03-26 |
北京安波特基因工程技术有限公司 |
基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
|
|
EP2295588B1
(en)
|
2004-05-27 |
2018-03-07 |
The Trustees Of The University Of Pennsylvania |
Novel artificial antigen presenting cells and uses thefor
|
|
BRPI0511755A
(pt)
|
2004-06-01 |
2008-01-02 |
Domantis Ltd |
composições, fusões e conjugados de drogas e métodos de produção, tratamento e utilização
|
|
JP2008512352A
(ja)
|
2004-07-17 |
2008-04-24 |
イムクローン システムズ インコーポレイティド |
新規な四価の二重特異性抗体
|
|
EP1634603A1
(de)
|
2004-08-26 |
2006-03-15 |
Eberhard-Karls-Universität Tübingen Universitätsklinikum |
Behandlung von transformierten oder infizierten biologischen Zellen
|
|
US20080069772A1
(en)
|
2004-08-26 |
2008-03-20 |
Eberhard-Karls-Universitaet Tuebingen Universitaetsklinikum |
Treatment of transformed or infected biological cells
|
|
FR2879605B1
(fr)
|
2004-12-16 |
2008-10-17 |
Centre Nat Rech Scient Cnrse |
Production de formats d'anticorps et applications immunologiques de ces formats
|
|
EP1752471B9
(en)
|
2005-01-05 |
2009-04-15 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
|
|
US8222376B2
(en)
|
2005-01-06 |
2012-07-17 |
Novo Nordisk A/S |
KIR-binding agents and methods of use thereof
|
|
ES2732623T3
(es)
|
2005-01-06 |
2019-11-25 |
Innate Pharma Sa |
Tratamientos y métodos de combinación anti-KIR
|
|
US7812135B2
(en)
|
2005-03-25 |
2010-10-12 |
Tolerrx, Inc. |
GITR-binding antibodies
|
|
US7833979B2
(en)
|
2005-04-22 |
2010-11-16 |
Amgen Inc. |
Toxin peptide therapeutic agents
|
|
US20060252096A1
(en)
|
2005-04-26 |
2006-11-09 |
Glycofi, Inc. |
Single chain antibody with cleavable linker
|
|
AU2006244885B2
(en)
|
2005-05-09 |
2011-03-31 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
|
|
EP1888640B1
(en)
|
2005-05-18 |
2012-03-14 |
Ablynx N.V. |
Improved nanobodies against tumor necrosis factor-alpha
|
|
NZ563392A
(en)
|
2005-05-20 |
2009-12-24 |
Ablynx Nv |
Improved Nanobodies(TM) for the treatment of aggregation-mediated disorders
|
|
EP1726650A1
(en)
|
2005-05-27 |
2006-11-29 |
Universitätsklinikum Freiburg |
Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
|
|
AU2006265108C1
(en)
|
2005-07-01 |
2013-01-17 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
|
|
NZ612578A
(en)
|
2005-08-19 |
2014-11-28 |
Abbvie Inc |
Dual variable domain immunoglobin and uses thereof
|
|
EP3178850B1
(en)
|
2005-10-11 |
2021-01-13 |
Amgen Research (Munich) GmbH |
Compositions comprising cross-species-specific antibodies and uses thereof
|
|
EP1934260B1
(en)
|
2005-10-14 |
2017-05-17 |
Innate Pharma |
Compositions and methods for treating proliferative disorders
|
|
GB0521991D0
(en)
|
2005-10-28 |
2005-12-07 |
Univ Dundee |
Siglec-9 binding agents
|
|
WO2007058823A2
(en)
|
2005-11-12 |
2007-05-24 |
Eli Lilly And Company |
Anti-egfr antibodies
|
|
WO2007062466A1
(en)
|
2005-11-29 |
2007-06-07 |
The University Of Sydney |
Demibodies: dimerisation-activated therapeutic agents
|
|
US7498142B2
(en)
|
2006-01-31 |
2009-03-03 |
Yeda Research And Development Co., Ltd. |
Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
|
|
US20110038854A1
(en)
|
2006-03-30 |
2011-02-17 |
University Of Medicine And Dentistry Of New Jersey |
Strategy for homo- or hetero-dimerization of various proteins in solution and in cell
|
|
WO2007113648A2
(en)
|
2006-04-05 |
2007-10-11 |
Pfizer Products Inc. |
Ctla4 antibody combination therapy
|
|
US20070269422A1
(en)
|
2006-05-17 |
2007-11-22 |
Ablynx N.V. |
Serum albumin binding proteins with long half-lives
|
|
US8629244B2
(en)
|
2006-08-18 |
2014-01-14 |
Ablynx N.V. |
Interleukin-6 receptor binding polypeptides
|
|
AU2007293614A1
(en)
|
2006-09-08 |
2008-03-13 |
Ablynx N.V. |
Serum albumin binding proteins with long half-lives
|
|
CN101557817A
(zh)
|
2006-09-14 |
2009-10-14 |
人类基因科学公司 |
清蛋白融合蛋白
|
|
US20100166734A1
(en)
|
2006-12-20 |
2010-07-01 |
Edward Dolk |
Oral delivery of polypeptides
|
|
EP2109460B1
(en)
|
2007-01-11 |
2016-05-18 |
Novo Nordisk A/S |
Anti-kir antibodies, formulations, and uses thereof
|
|
KR101589759B1
(ko)
|
2007-04-03 |
2016-01-29 |
암젠 리서치 (뮌헨) 게엠베하 |
종간 특이적 ｃｄ３―입실론 결합 도메인
|
|
WO2008119566A2
(en)
*
|
2007-04-03 |
2008-10-09 |
Micromet Ag |
Cross-species-specific bispecific binders
|
|
JP2008278814A
(ja)
|
2007-05-11 |
2008-11-20 |
Igaku Seibutsugaku Kenkyusho:Kk |
アゴニスティック抗ヒトｇｉｔｒ抗体による免疫制御の解除とその応用
|
|
US8623361B2
(en)
|
2007-05-24 |
2014-01-07 |
Ablynx N.V. |
Amino acid sequences directed against RANK-L and polypeptides comprising the same for the treatment of bone diseases and disorders
|
|
EP2176298B1
(en)
|
2007-05-30 |
2017-11-15 |
Xencor, Inc. |
Methods and compositions for inhibiting cd32b expressing cells
|
|
CA2691357C
(en)
|
2007-06-18 |
2014-09-23 |
N.V. Organon |
Antibodies to human programmed death receptor pd-1
|
|
EP2014680A1
(en)
|
2007-07-10 |
2009-01-14 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
|
|
EP2175884B8
(en)
|
2007-07-12 |
2017-02-22 |
GITR, Inc. |
Combination therapies employing gitr binding molecules
|
|
EP2170960B1
(en)
|
2007-07-13 |
2015-07-29 |
Bac Ip B.V. |
Single-domain antigen-binding proteins that bind mammalian igg
|
|
JP6035009B2
(ja)
|
2007-08-22 |
2016-11-30 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
活性化可能な結合ポリペプチドおよびその同定方法ならびに使用
|
|
AU2007358569B2
(en)
|
2007-09-07 |
2014-09-04 |
Ablynx N.V. |
Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
|
|
US7982016B2
(en)
|
2007-09-10 |
2011-07-19 |
Amgen Inc. |
Antigen binding proteins capable of binding thymic stromal lymphopoietin
|
|
CN101842387B
(zh)
|
2007-09-26 |
2014-05-07 |
Ucb医药有限公司 |
双特异性抗体融合物
|
|
RU2010133892A
(ru)
|
2008-01-24 |
2012-02-27 |
Ново Нордиск А/С (DK) |
Гуманизированные моноклональные антитела против человеческого nkg2a
|
|
EP2242773B1
(en)
|
2008-02-11 |
2017-06-14 |
Cure Tech Ltd. |
Monoclonal antibodies for tumor treatment
|
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
|
HUE042053T2
(hu)
|
2008-06-05 |
2019-06-28 |
Ablynx Nv |
Vírus burokfehérjéi elleni aminosav-szekvenciák és az azokat tartalmazó polipeptidek virális betegségek kezelésére
|
|
US20100122358A1
(en)
|
2008-06-06 |
2010-05-13 |
Crescendo Biologics Limited |
H-Chain-only antibodies
|
|
KR20110044992A
(ko)
|
2008-07-02 |
2011-05-03 |
이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 |
ＴＧＦ-β 길항제 다중-표적 결합 단백질
|
|
US8444976B2
(en)
|
2008-07-02 |
2013-05-21 |
Argen-X B.V. |
Antigen binding polypeptides
|
|
DE102008036127A1
(de)
|
2008-08-01 |
2010-02-04 |
Emitec Gesellschaft Für Emissionstechnologie Mbh |
Verfahren zum Betrieb einer Abgasanlage mit Lambda-Regelung
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
MX2011002250A
(es)
|
2008-08-25 |
2011-08-17 |
Amplimmune Inc |
Antagonistas de muerte celular programada-1 y métodos de uso de los mismos.
|
|
HUE027525T2
(en)
|
2008-08-25 |
2016-11-28 |
Amplimmune Inc |
PD-1 Antagonist preparations and their use
|
|
DK2356153T3
(en)
|
2008-10-01 |
2016-07-04 |
Amgen Res Munich Gmbh |
Bispecific single CHAIN PSMAXCD3 ANTIBODY THAT ARE SPECIFICALLY TO ALL SPECIES
|
|
CA2738568C
(en)
|
2008-10-01 |
2024-02-20 |
Micromet Ag |
Cross-species-specific single domain bispecific single chain antibody
|
|
CA2738566C
(en)
|
2008-10-01 |
2024-04-30 |
Micromet Ag |
Bispecific single chain antibodies with specificity for high molecular weight target antigens
|
|
US9327022B2
(en)
|
2008-10-14 |
2016-05-03 |
National Research Council Of Canada |
BSA-specific antibodies
|
|
US8709411B2
(en)
|
2008-12-05 |
2014-04-29 |
Novo Nordisk A/S |
Combination therapy to enhance NK cell mediated cytotoxicity
|
|
WO2010077643A1
(en)
|
2008-12-08 |
2010-07-08 |
Tegopharm Corporation |
Masking ligands for reversible inhibition of multivalent compounds
|
|
PT2376535T
(pt)
|
2008-12-09 |
2017-06-23 |
Hoffmann La Roche |
Anticorpos anti-pd-l1 e a sua utilização para a melhoria do funcionamento das células t
|
|
US9345787B2
(en)
|
2008-12-22 |
2016-05-24 |
Targovax Oy |
Adenoviral vectors and methods and uses related thereto
|
|
US20100189651A1
(en)
|
2009-01-12 |
2010-07-29 |
Cytomx Therapeutics, Llc |
Modified antibody compositions, methods of making and using thereof
|
|
EP2210902A1
(en)
|
2009-01-14 |
2010-07-28 |
TcL Pharma |
Recombinant monovalent antibodies
|
|
EP3192811A1
(en)
|
2009-02-09 |
2017-07-19 |
Université d'Aix-Marseille |
Pd-1 antibodies and pd-l1 antibodies and uses thereof
|
|
SG10201402960SA
(en)
|
2009-03-05 |
2014-08-28 |
Abbvie Inc |
IL-17 Binding Proteins
|
|
HUE049825T2
(hu)
|
2009-09-03 |
2020-10-28 |
Merck Sharp & Dohme |
Anti-GITR antitestek
|
|
US20110195494A1
(en)
|
2009-10-02 |
2011-08-11 |
Boehringer Ingelheim International Gmbh |
Dll4-binging molecules
|
|
WO2011051327A2
(en)
|
2009-10-30 |
2011-05-05 |
Novartis Ag |
Small antibody-like single chain proteins
|
|
EP2504028A4
(en)
|
2009-11-24 |
2014-04-09 |
Amplimmune Inc |
SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
|
|
CN107337734A
(zh)
*
|
2009-12-04 |
2017-11-10 |
弗·哈夫曼-拉罗切有限公司 |
多特异性抗体、抗体类似物、组合物和方法
|
|
EP2332994A1
(en)
|
2009-12-09 |
2011-06-15 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Trispecific therapeutics against acute myeloid leukaemia
|
|
MY159679A
(en)
|
2009-12-10 |
2017-01-13 |
Hoffmann La Roche |
Antibodies binding preferentially human csf1r extracellular domain 4 and their use
|
|
US20110165161A1
(en)
|
2009-12-23 |
2011-07-07 |
Shih-Yao Lin |
Anti-epcam antibodies that induce apoptosis of cancer cells and methods using same
|
|
JP5851419B2
(ja)
|
2009-12-29 |
2016-02-03 |
エマージェント プロダクト デベロップメント シアトル， エルエルシー |
ヘテロダイマー結合タンパク質およびその使用
|
|
GB2476681B
(en)
|
2010-01-04 |
2012-04-04 |
Argen X Bv |
Humanized camelid VH, VK and VL immunoglobulin domains
|
|
PT2530091T
(pt)
|
2010-01-29 |
2018-05-17 |
Chugai Pharmaceutical Co Ltd |
Anticorpo anti-dll3
|
|
RU2617971C2
(ru)
|
2010-03-05 |
2017-04-28 |
Ф.Хоффманн-Ля Рош Аг |
Антитела против csf-1r человека и их применение
|
|
MX336682B
(es)
|
2010-03-05 |
2016-01-27 |
Hoffmann La Roche |
Anticuerpos contra csf-1r humanos y usos de los mismos.
|
|
EP2550529B1
(en)
|
2010-03-23 |
2021-11-17 |
Iogenetics, LLC. |
Bioinformatic processes for determination of peptide binding
|
|
EP2552962B1
(en)
|
2010-03-26 |
2016-03-23 |
Ablynx N.V. |
Immunoglobulin single variable domains directed against cxcr7
|
|
US9556273B2
(en)
|
2010-03-29 |
2017-01-31 |
Vib Vzw |
Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
|
|
KR20200044999A
(ko)
|
2010-05-04 |
2020-04-29 |
파이브 프라임 테라퓨틱스, 인크. |
Ｃｓｆ1ｒ에 결합하는 항체들
|
|
WO2011155607A1
(ja)
|
2010-06-11 |
2011-12-15 |
協和発酵キリン株式会社 |
抗ｔｉｍ－３抗体
|
|
PL391627A1
(pl)
|
2010-06-25 |
2012-01-02 |
Adamed Spółka Z Ograniczoną Odpowiedzialnością |
Przeciwnowotworowe białko fuzyjne
|
|
CA3086837C
(en)
|
2010-07-16 |
2023-03-07 |
Adimab, Llc |
Libraries comprising segmental pools, and methods for their preparation and use
|
|
CA2807664A1
(en)
|
2010-08-12 |
2012-02-16 |
Theraclone Sciences, Inc. |
Anti-hemagglutinin antibody compositions and methods of use thereof
|
|
CA2807269A1
(en)
|
2010-08-24 |
2012-03-01 |
Roche Glycart Ag |
Activatable bispecific antibodies
|
|
WO2012025530A1
(en)
|
2010-08-24 |
2012-03-01 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies comprising a disulfide stabilized - fv fragment
|
|
EP2621953B1
(en)
|
2010-09-30 |
2017-04-05 |
Ablynx N.V. |
Biological materials related to c-met
|
|
WO2012066058A1
(en)
|
2010-11-16 |
2012-05-24 |
Boehringer Ingelheim International Gmbh |
Agents and methods for treating diseases that correlate with bcma expression
|
|
TWI664191B
(zh)
|
2010-11-22 |
2019-07-01 |
天賜製藥公司 |
Ｎｋ細胞調節治療及治療血液惡性疾病之方法
|
|
MX360254B
(es)
|
2011-03-10 |
2018-10-26 |
Pfizer |
Combinacion de terapias inmunomoduladoras local y sistemica para tratamiento mejorado del cancer.
|
|
US9029113B2
(en)
|
2011-03-11 |
2015-05-12 |
Kaneka Corporation |
Modified aminotransferase, gene thereof, and method for producing optically active amino compound using same
|
|
WO2012131053A1
(en)
|
2011-03-30 |
2012-10-04 |
Ablynx Nv |
Methods of treating immune disorders with single domain antibodies against tnf-alpha
|
|
CN107188969B
(zh)
|
2011-04-08 |
2021-08-27 |
美国卫生和人力服务部 |
抗-表皮生长因子受体变体iii嵌合抗原受体及其用于治疗癌症的用途
|
|
WO2012143524A2
(en)
*
|
2011-04-20 |
2012-10-26 |
Genmab A/S |
Bispecific antibodies against her2 and cd3
|
|
RS57324B1
(sr)
|
2011-04-20 |
2018-08-31 |
Medimmune Llc |
Antitela i drugi molekuli koji vezuju b7-h1 i pd-1
|
|
JP6400470B2
(ja)
|
2011-05-16 |
2018-10-03 |
ジェネロン（シャンハイ）コーポレイション リミテッド |
多重特異性Ｆａｂ融合タンパク質および使用法
|
|
EA201391753A1
(ru)
|
2011-05-21 |
2014-08-29 |
Макродженикс, Инк. |
Домены, связывающиеся с деиммунизованной сывороткой, и их применение для увеличения времени полужизни в сыворотке
|
|
BR112013030017A2
(pt)
|
2011-05-25 |
2020-10-13 |
Innate Pharma Sa |
anticorpos anti-kir para o tratamento de distúrbios inflamatórios
|
|
CA2833820C
(en)
|
2011-05-27 |
2019-10-29 |
Glaxo Group Limited |
Bcma (cd269/tnfrsf17) -binding proteins
|
|
EP4218933A1
(en)
|
2011-06-23 |
2023-08-02 |
Ablynx NV |
Serum albumin binding proteins
|
|
WO2013006490A2
(en)
|
2011-07-01 |
2013-01-10 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to tim3
|
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
|
US20150158934A1
(en)
|
2011-09-09 |
2015-06-11 |
Ucl Business Plc |
Broadly neutralizing vhh against hiv-1
|
|
US20130108641A1
(en)
|
2011-09-14 |
2013-05-02 |
Sanofi |
Anti-gitr antibodies
|
|
AU2012311451B2
(en)
|
2011-09-23 |
2017-08-10 |
Universitat Stuttgart |
Serum half-life extension using immunoglobulin binding domains
|
|
EP2747783B1
(en)
|
2011-09-30 |
2017-06-14 |
Ablynx N.V. |
Biological materials related to c-met
|
|
ES2546317T3
(es)
|
2011-10-11 |
2015-09-22 |
Ucb Biopharma Sprl |
Derivados de 2-oxo-piperidinilo
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
CA2856895C
(en)
|
2011-11-28 |
2021-10-26 |
Merck Patent Gmbh |
Anti-pd-l1 antibodies and uses thereof
|
|
CN104159921B
(zh)
|
2011-12-15 |
2018-05-04 |
霍夫曼-拉罗奇有限公司 |
针对人csf-1r的抗体及其用途
|
|
US9642918B2
(en)
|
2011-12-16 |
2017-05-09 |
Pfizer Inc. |
Combination of inotuzumab ozogamicin and torisel for the treatment of cancer
|
|
US9481724B2
(en)
|
2011-12-19 |
2016-11-01 |
The Rockefeller University |
hDC-sign binding peptides
|
|
ES2653287T3
(es)
|
2012-01-13 |
2018-02-06 |
Julius-Maximilians-Universität Würzburg |
Complementación funcional bipartita inducida por antígenos duales
|
|
WO2013110531A1
(en)
|
2012-01-23 |
2013-08-01 |
Ablynx Nv |
Sequences directed against hepatocyte growth factor (hgf) and polypeptides comprising the same for the treatment of cancers and/or tumors
|
|
CA2861122A1
(en)
|
2012-02-06 |
2013-08-15 |
Genentech, Inc. |
Compositions and methods for using csf1r inhibitors
|
|
US10040846B2
(en)
|
2012-02-22 |
2018-08-07 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer
|
|
CN104520324A
(zh)
|
2012-02-24 |
2015-04-15 |
施特姆森特Rx股份有限公司 |
Dll3调节剂及其使用方法
|
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
|
US20150037334A1
(en)
|
2012-03-01 |
2015-02-05 |
Amgen Research (Munich) Gmbh |
Long life polypeptide binding molecules
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
EP2841082A4
(en)
|
2012-03-30 |
2015-12-30 |
Bayer Healthcare Llc |
ANTIBODIES REGULATED BY PROTEASES
|
|
MX366813B
(es)
|
2012-04-20 |
2019-07-25 |
Aptevo Res & Development Llc |
Polipeptidos de enlace cd3.
|
|
WO2013163631A2
(en)
|
2012-04-27 |
2013-10-31 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
|
|
EP3539984A1
(en)
|
2012-05-11 |
2019-09-18 |
Five Prime Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
|
|
CA3213528A1
(en)
|
2012-05-15 |
2013-11-21 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
|
|
KR101566538B1
(ko)
|
2012-06-08 |
2015-11-05 |
국립암센터 |
신규한 Ｔｈ17 세포 전환용 에피토프 및 이의 용도
|
|
WO2013192546A1
(en)
|
2012-06-22 |
2013-12-27 |
Cytomx Therapeutics, Inc. |
Activatable antibodies having non-binding steric moieties and mehtods of using the same
|
|
WO2014004549A2
(en)
|
2012-06-27 |
2014-01-03 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
|
AR091649A1
(es)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
|
|
RU2650868C2
(ru)
|
2012-07-13 |
2018-04-17 |
Займворкс Инк. |
Биспецифические асимметричные гетеродимеры, содержащие анти-cd3 конструкции
|
|
CN112587671A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
|
TWI713436B
(zh)
|
2012-08-31 |
2020-12-21 |
美商戊瑞治療有限公司 |
用結合群落刺激因子１受體（ｃｓｆ１ｒ）之抗體治療病狀之方法
|
|
EP2890709A2
(en)
|
2012-08-31 |
2015-07-08 |
arGEN-X N.V. |
Highly diverse combinatorial antibody libraries
|
|
KR101963231B1
(ko)
|
2012-09-11 |
2019-03-28 |
삼성전자주식회사 |
이중특이 항체의 제작을 위한 단백질 복합체 및 이를 이용한 이중특이 항체 제조 방법
|
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
|
AU2013324049B2
(en)
|
2012-09-27 |
2017-09-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mesothelin antibodies and methods for eliciting potent antitumor activity
|
|
HUE035503T2
(en)
|
2012-10-02 |
2018-05-02 |
Bristol Myers Squibb Co |
Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
|
|
NZ707895A
(en)
*
|
2012-11-06 |
2019-07-26 |
Bayer Pharma AG |
Formulation for bispecific t-cell engagers (bites)
|
|
US9243058B2
(en)
|
2012-12-07 |
2016-01-26 |
Amgen, Inc. |
BCMA antigen binding proteins
|
|
EP3575326B8
(en)
|
2012-12-17 |
2022-05-25 |
Trillium Therapeutics ULC |
Treatment of cd47+ disease cells with sirp alpha-fc fusions
|
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
|
GB201302447D0
(en)
|
2013-02-12 |
2013-03-27 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
|
RU2684468C2
(ru)
|
2013-02-22 |
2019-04-09 |
ЭББВИ СТЕМСЕНТРКС ЭлЭлСи |
Новые конъюгаты антител и их применения
|
|
EA201591501A1
(ru)
|
2013-02-28 |
2016-02-29 |
Юниверсити Корт Ов Де Юниверсити Ов Эдинбург |
Терапевтические средства на основе csf-1
|
|
AU2014225788B2
(en)
|
2013-03-05 |
2018-03-29 |
Baylor College Of Medicine |
Engager cells for immunotherapy
|
|
WO2014160030A2
(en)
|
2013-03-13 |
2014-10-02 |
Health Research, Inc. |
Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen
|
|
ES2790420T3
(es)
|
2013-03-14 |
2020-10-27 |
Scripps Research Inst |
Conjugados de anticuerpos y de agentes de focalización usos de los mismos
|
|
EP2970494B1
(en)
|
2013-03-14 |
2017-12-13 |
The Board of Regents of The University of Texas System |
Her3 specific monoclonal antibodies for diagnostic and therapeutic use
|
|
EP2970484B2
(en)
|
2013-03-15 |
2022-09-21 |
Amgen Inc. |
Heterodimeric bispecific antibodies
|
|
US20140302037A1
(en)
|
2013-03-15 |
2014-10-09 |
Amgen Inc. |
BISPECIFIC-Fc MOLECULES
|
|
AR095596A1
(es)
|
2013-03-15 |
2015-10-28 |
Amgen Res Munich Gmbh |
Moléculas de unión de cadena única comprendiendo n-terminal abp
|
|
US20140308285A1
(en)
|
2013-03-15 |
2014-10-16 |
Amgen Inc. |
Heterodimeric bispecific antibodies
|
|
TWI654206B
(zh)
|
2013-03-16 |
2019-03-21 |
諾華公司 |
使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
|
|
EA035322B1
(ru)
|
2013-05-28 |
2020-05-28 |
ДиЭсБи-ЮЭсЭй ЛЛК |
Антитело с "запирающими" свойствами для инактивации лекарства белкового происхождения
|
|
RU2727836C2
(ru)
|
2013-07-25 |
2020-07-24 |
Сайтомкс Терапьютикс, Инк. |
Мультспецифические антитела, мультспецифические активируемые антитела и способы их применения
|
|
JP2016529892A
(ja)
|
2013-08-01 |
2016-09-29 |
ユニベルシテ カソリク デ ロウバイン |
抗ｇａｒｐタンパク質及びその使用
|
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
|
RU2016111137A
(ru)
|
2013-08-28 |
2017-10-03 |
ЭББВИ СТЕМСЕНТРКС ЭлЭлСи |
Сконструированные конъюгаты против dll3 и способы применения
|
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
CA3078121A1
(en)
|
2013-09-13 |
2015-03-19 |
Beigene Switzerland Gmbh |
Anti-pd1 antibodies and their use as therapeutics and diagnostics
|
|
EP3508502B1
(en)
|
2013-09-20 |
2023-04-26 |
Bristol-Myers Squibb Company |
Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
|
|
ES2638320T3
(es)
|
2013-09-24 |
2017-10-19 |
University Of Washington Through Its Center For Commercialization |
Proteínas de unión a desmogleina 2 (DSG2) y sus usos
|
|
ES2779123T3
(es)
|
2013-09-26 |
2020-08-13 |
Ablynx Nv |
Nanobodies biespecíficos
|
|
US20160263087A1
(en)
|
2013-11-08 |
2016-09-15 |
Iteos Therapeutics |
Novel 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
|
|
US9126984B2
(en)
|
2013-11-08 |
2015-09-08 |
Iteos Therapeutics |
4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
|
|
EP3082802B1
(en)
|
2013-12-03 |
2020-02-26 |
Iomet Pharma Ltd. |
Tryptophan-2,3-dioxygenase (tdo) and/or indolamine-2,3-dioxygenase (ido) inhibitors and their use
|
|
WO2015103072A1
(en)
|
2013-12-30 |
2015-07-09 |
Epimab Biotherapeutics |
Fabs-in-tandem immunoglobulin and uses thereof
|
|
JP2017505346A
(ja)
|
2014-02-12 |
2017-02-16 |
アイティーオス セラペウティクス |
新規な３−（インドール−３−イル）−ピリジン誘導体、医薬組成物、および使用方法
|
|
AU2015218633A1
(en)
|
2014-02-21 |
2016-09-01 |
Abbvie Stemcentrx Llc |
Anti-DLL3 antibodies and drug conjugates for use in melanoma
|
|
ES2939760T3
(es)
|
2014-03-15 |
2023-04-26 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico para antígenos
|
|
EP3119763A1
(en)
|
2014-03-18 |
2017-01-25 |
Iteos Therapeutics |
Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use
|
|
CA2943167A1
(en)
|
2014-03-24 |
2015-10-01 |
University Of Southampton |
Modified antibodies containing modified igg2 domains which elicit agonist or antagonistic properties and use thereof
|
|
WO2015146437A1
(ja)
|
2014-03-25 |
2015-10-01 |
国立大学法人東北大学 |
高機能性ＩｇＧ２型二重特異性抗体
|
|
FI3708579T3
(fi)
|
2014-04-01 |
2024-07-16 |
Biontech Cell & Gene Therapies Gmbh |
Claudin-6-spesifiset immuunoreseptorit ja t-soluepitoopit
|
|
UA117289C2
(uk)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифічне антитіло
|
|
DK3125883T3
(da)
|
2014-04-04 |
2020-10-19 |
Iomet Pharma Ltd |
Indolderivater til anvendelse i medicin
|
|
JP2017518965A
(ja)
|
2014-05-02 |
2017-07-13 |
モメンタ ファーマシューティカルズ インコーポレイテッ |
エンジニアリングされたＦｃ構築物に関連する組成物および方法
|
|
MD20160118A2
(ro)
|
2014-05-15 |
2017-04-30 |
Iteos Therapeutics |
Derivaţi ai pirolidin-2,5-dionei, compoziţii farmaceutice şi metode de utilizare ca inhibitori ai IDO1
|
|
RS61678B1
(sr)
|
2014-05-28 |
2021-05-31 |
Agenus Inc |
Anti-gitr antitela i postupci za njihovu primenu
|
|
AU2015266880B2
(en)
|
2014-05-29 |
2019-03-21 |
Macrogenics, Inc. |
Tri-Specific Binding Molecules and methods of use thereof
|
|
SMT201900668T1
(it)
|
2014-06-06 |
2020-01-14 |
Bristol Myers Squibb Co |
Anticorpi contro il recettore per il fattore di necrosi tumorale indotto da glucocorticoidi(gitr)e loro usi
|
|
GB201412659D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
|
KR102612313B1
(ko)
|
2014-07-21 |
2023-12-12 |
노파르티스 아게 |
인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료
|
|
EP3172235A2
(en)
|
2014-07-25 |
2017-05-31 |
Cytomx Therapeutics Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
|
AR101669A1
(es)
|
2014-07-31 |
2017-01-04 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
|
AR101400A1
(es)
|
2014-07-31 |
2016-12-14 |
Amgen Res Munich Gmbh |
Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido
|
|
GB201414730D0
(en)
|
2014-08-19 |
2014-10-01 |
Tpp Global Dev Ltd |
Pharmaceutical compound
|
|
SG11201701385WA
(en)
|
2014-08-28 |
2017-03-30 |
Academisch Ziekenhuis Leiden |
Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations
|
|
CN105471609B
(zh)
|
2014-09-05 |
2019-04-05 |
华为技术有限公司 |
一种用于配置业务的方法和装置
|
|
RS60305B1
(sr)
|
2014-09-05 |
2020-07-31 |
Janssen Pharmaceutica Nv |
Agensi koji vezuju cd123 i njihove upotrebe
|
|
EP3191517B1
(en)
|
2014-09-10 |
2020-11-04 |
Innate Pharma |
Cross reactive siglec antibodies
|
|
CA2959463A1
(en)
|
2014-09-16 |
2016-03-24 |
Innate Pharma |
Treatment regimens using anti-nkg2a antibodies
|
|
US20170247476A1
(en)
|
2014-09-25 |
2017-08-31 |
Amgen Inc. |
Protease-activatable bispecific proteins
|
|
EP3204491A1
(en)
|
2014-10-07 |
2017-08-16 |
Cellectis |
Method for modulating car-induced immune cells activity
|
|
EP3215156B1
(en)
|
2014-11-03 |
2025-09-24 |
Iomet Pharma Ltd. |
Inhibitors of tryptophan-2,3-dioxygenase or indoleamine-2,3-dioxygenase
|
|
GB201419579D0
(en)
|
2014-11-03 |
2014-12-17 |
Iomet Pharma Ltd |
Pharmaceutical compound
|
|
MY191423A
(en)
|
2014-11-10 |
2022-06-27 |
Medimmune Ltd |
Binding molecules specific for cd73 and uses thereof
|
|
BR112017011166A2
(pt)
|
2014-11-26 |
2018-02-27 |
Xencor, Inc. |
anticorpos heterodiméricos que se ligam a cd3 e cd38
|
|
EP3029068A1
(en)
|
2014-12-03 |
2016-06-08 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
|
|
US11001625B2
(en)
|
2014-12-10 |
2021-05-11 |
Tufts University |
VHH based binding antibodies for anthrax and botulinum toxins and methods of making and using therefor
|
|
US10428155B2
(en)
*
|
2014-12-22 |
2019-10-01 |
Xencor, Inc. |
Trispecific antibodies
|
|
BR112017015136A2
(pt)
|
2015-01-14 |
2018-01-30 |
Compass Therapeutics Llc |
polipeptídeo de construto de ligação ao antígeno imunomodulador multiespecífico, construto de ligação ao antígeno imunomodulador multiespecífico, conjugado, composição farmacêutica, método para tratar um indivíduo com câncer, método para inibir ou reduzir o crescimento de câncer, composição, célula, método de fazer um polipeptídeo de construto de ligação ao antígeno imunomodulador multiespecífico, vetor ou conjunto de vetores e kit
|
|
EP3253796A1
(en)
|
2015-02-03 |
2017-12-13 |
Université Catholique de Louvain |
Anti-garp protein and uses thereof
|
|
JP6772157B2
(ja)
|
2015-02-05 |
2020-10-21 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． |
インフルエンザヘマグルチニンに対する結合分子及びその使用
|
|
EP3256495A4
(en)
|
2015-02-11 |
2018-09-19 |
Aptevo Research and Development LLC |
Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins
|
|
DK3259597T3
(da)
|
2015-02-19 |
2022-05-09 |
Compugen Ltd |
Pvrig-polypeptider og fremgangsmåder til behandling
|
|
PT3653221T
(pt)
|
2015-02-19 |
2022-11-08 |
Compugen Ltd |
Anticorpos anti-pvrig e métodos de utilização
|
|
MA41613A
(fr)
|
2015-02-23 |
2018-01-02 |
Abbvie Stemcentrx Llc |
Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
|
|
EP3271354A1
(en)
|
2015-03-17 |
2018-01-24 |
Pfizer Inc |
Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use
|
|
EP3286320A2
(en)
|
2015-04-22 |
2018-02-28 |
Agbiome, Inc. |
Insecticidal genes and methods of use
|
|
CN107709363A
(zh)
|
2015-05-01 |
2018-02-16 |
基因泰克公司 |
掩蔽抗cd3抗体和使用方法
|
|
EP3291836A4
(en)
|
2015-05-06 |
2018-11-14 |
Janssen Biotech, Inc. |
Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
|
|
RS65904B1
(sr)
|
2015-05-13 |
2024-09-30 |
Ablynx Nv |
Polipeptidi koji regrutuju t ćelije na osnovu reaktivnosti cd3
|
|
WO2016182064A1
(ja)
|
2015-05-13 |
2016-11-17 |
中外製薬株式会社 |
多重抗原結合分子融合体、医薬組成物、線状エピトープの同定方法、および多重抗原結合分子融合体の製造方法
|
|
WO2016181348A1
(en)
|
2015-05-14 |
2016-11-17 |
Pfizer Inc. |
Combinations comprising a pyrrolidine-2,5-dione ido1 inhibitor and an anti-body
|
|
US10526597B2
(en)
|
2015-05-21 |
2020-01-07 |
Full Spectrum Genetics, Inc. |
Method of improving characteristics of proteins
|
|
WO2016187594A1
(en)
|
2015-05-21 |
2016-11-24 |
Harpoon Therapeutics, Inc. |
Trispecific binding proteins and methods of use
|
|
MA55776A
(fr)
|
2015-06-03 |
2022-03-02 |
Agbiome Inc |
Gènes pesticides et procédés d'utilisation
|
|
CN107709356A
(zh)
|
2015-06-26 |
2018-02-16 |
南加利福尼亚大学 |
用于肿瘤特异性活化的掩蔽嵌合抗原受体t细胞
|
|
GB201511790D0
(en)
|
2015-07-06 |
2015-08-19 |
Iomet Pharma Ltd |
Pharmaceutical compound
|
|
SI3115376T1
(sl)
|
2015-07-10 |
2018-12-31 |
Merus N.V. |
Humana protitelesa, ki vežejo CD3
|
|
CA2991799A1
(en)
|
2015-07-15 |
2017-01-19 |
Zymeworks Inc. |
Drug-conjugated bi-specific antigen-binding constructs
|
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究（慕尼黑）公司 |
Ｆｌｔ３及ｃｄ３抗體構築體
|
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究（慕尼黑）公司 |
Ｍｓｌｎ及ｃｄ３抗體構築體
|
|
TWI793062B
(zh)
|
2015-07-31 |
2023-02-21 |
德商安美基研究（慕尼黑）公司 |
Ｄｌｌ３及ｃｄ３抗體構築體
|
|
WO2017021450A1
(en)
|
2015-08-03 |
2017-02-09 |
Engmab Ag |
Monoclonal antibodies against bcma
|
|
WO2017027392A1
(en)
|
2015-08-07 |
2017-02-16 |
Novartis Ag |
Treatment of cancer using chimeric cd3 receptor proteins
|
|
EP3334733A1
(en)
|
2015-08-10 |
2018-06-20 |
Pfizer Inc |
3-indol substituted derivatives, pharmaceutical compositions and methods for use
|
|
WO2017025698A1
(en)
|
2015-08-11 |
2017-02-16 |
Queen Mary University Of London |
Bispecific, cleavable antibodies
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
UA127515C2
(uk)
|
2015-08-17 |
2023-09-20 |
Янссен Байотек, Інк. |
Антитіло до всма, біспецифічна антигензв'язувальна молекула, що зв'язує всма і cd3, і їх використання
|
|
MX2018002166A
(es)
|
2015-08-20 |
2018-09-12 |
Abbvie Stemcentrx Llc |
Conjugados anticuerpo anti-dll3-farmaco y metodos de uso.
|
|
CN106519037B
(zh)
|
2015-09-11 |
2019-07-23 |
科济生物医药（上海）有限公司 |
可活化的嵌合受体
|
|
MY194586A
(en)
|
2015-09-24 |
2022-12-05 |
Daiichi Sankyo Co Ltd |
Anti-garp antibody
|
|
CN116003596A
(zh)
|
2015-10-29 |
2023-04-25 |
艾利妥 |
抗siglec-9抗体及其使用方法
|
|
JP2018537970A
(ja)
|
2015-11-05 |
2018-12-27 |
シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ |
養子ｔ細胞療法のための細胞を調製する方法
|
|
MX377351B
(es)
|
2015-11-19 |
2025-03-07 |
Genentech Inc |
Metodos para el tratamiento de cancer utilizando inhibidores b-raf e inhibidores de punto de control inmunologico
|
|
US10035856B2
(en)
|
2015-11-19 |
2018-07-31 |
Revitope Limited |
Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
|
|
CA3006432A1
(en)
|
2015-12-04 |
2017-06-08 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
CA3011092A1
(en)
|
2016-01-12 |
2017-07-20 |
Palleon Pharmaceuticals Inc. |
Use of siglec-7 or siglec-9 antibodies for the treatment of cancer
|
|
US9624185B1
(en)
|
2016-01-20 |
2017-04-18 |
Yong Xu |
Method for preparing IDO inhibitor epacadostat
|
|
KR102688969B1
(ko)
|
2016-02-03 |
2024-07-30 |
암젠 리서치 (뮌헨) 게엠베하 |
Bcma 및 cd3 이중특이성 t 세포 맞물림 항체 작제물
|
|
WO2017136549A1
(en)
|
2016-02-03 |
2017-08-10 |
Youhealth Biotech, Limited |
Compounds for treating eye disorders or diseases
|
|
MA43816A
(fr)
|
2016-03-08 |
2018-11-28 |
Maverick Therapeutics Inc |
Protéines de liaison inductibles et méthodes d'utilisation
|
|
US10870701B2
(en)
|
2016-03-15 |
2020-12-22 |
Generon (Shanghai) Corporation Ltd. |
Multispecific fab fusion proteins and use thereof
|
|
WO2017161206A1
(en)
|
2016-03-16 |
2017-09-21 |
Halozyme, Inc. |
Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
|
|
SG11201808085WA
(en)
|
2016-03-22 |
2018-10-30 |
Hoffmann La Roche |
Protease-activated t cell bispecific molecules
|
|
EP3436480A4
(en)
|
2016-03-30 |
2019-11-27 |
Musc Foundation for Research Development |
METHOD FOR THE TREATMENT AND DIAGNOSIS OF CANCER BY TARGETING GLYCOPROTEIN A REPETITION PREDOMINANT (GARP) AND FOR EFFECTIVE IMMUNOTHERAPY ALONE OR IN COMBINATION
|
|
CA3024683A1
(en)
|
2016-05-20 |
2017-11-23 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment cd3 binding proteins
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
TW201800111A
(zh)
|
2016-05-20 |
2018-01-01 |
艾伯維史坦森特瑞斯有限責任公司 |
用於治療具有神經內分泌轉型風險之腫瘤的抗dll3藥物結合物
|
|
JP7101621B2
(ja)
|
2016-05-20 |
2022-07-15 |
ハープーン セラピューティクス，インク． |
単一ドメイン血清アルブミン結合タンパク質
|
|
US20170349660A1
(en)
|
2016-06-01 |
2017-12-07 |
Xencor. Inc. |
Bispecific antibodies that bind cd123 and cd3
|
|
RU2769282C2
(ru)
|
2016-06-20 |
2022-03-30 |
Кимаб Лимитед |
Анти-PD-L1 и IL-2 цитокины
|
|
WO2018017864A2
(en)
|
2016-07-20 |
2018-01-25 |
Oncomed Pharmaceuticals, Inc. |
Pvrig-binding agents and uses thereof
|
|
TW201815825A
(zh)
|
2016-07-21 |
2018-05-01 |
財團法人生物技術開發中心 |
經修飾之抗原結合fab片段及包含其之抗原結合分子
|
|
EP3494138A1
(en)
|
2016-08-02 |
2019-06-12 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
JP7137563B2
(ja)
|
2016-08-05 |
2022-09-14 |
アラコス，インコーポレイティド |
がん治療用の抗Ｓｉｇｌｅｃ－７抗体
|
|
US11324744B2
(en)
|
2016-08-08 |
2022-05-10 |
Acetylon Pharmaceuticals Inc. |
Methods of use and pharmaceutical combinations of histone deacetylase inhibitors and CD20 inhibitory antibodies
|
|
KR20230145510A
(ko)
|
2016-08-17 |
2023-10-17 |
컴퓨젠 엘티디. |
항-tigit 항체, 항-pvrig 항체 및 이들의 조합
|
|
WO2018048975A1
(en)
|
2016-09-09 |
2018-03-15 |
Bristol-Myers Squibb Company |
Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
|
|
US20190225702A1
(en)
|
2016-10-14 |
2019-07-25 |
Harpoon Therapeutics, Inc. |
Innate immune cell trispecific binding proteins and methods of use
|
|
EP3526246A1
(en)
|
2016-10-17 |
2019-08-21 |
Vetoquinol SA |
Modified antibody constant region
|
|
WO2018075359A1
(en)
|
2016-10-18 |
2018-04-26 |
Boger Henry William |
Wireless power transfer for process control
|
|
JP2019537438A
(ja)
|
2016-11-01 |
2019-12-26 |
アナプティスバイオ インコーポレイティッド |
Ｔｉｍ−３（ｔ細胞イムノグロブリンおよびムチンタンパク質３）に対する抗体
|
|
EP4295918A3
(en)
|
2016-11-02 |
2024-03-20 |
Bristol-Myers Squibb Company |
Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
|
|
CA3044729A1
(en)
|
2016-11-23 |
2018-05-31 |
Harpoon Therapeutics, Inc. |
Psma targeting trispecific proteins and methods of use
|
|
KR20210087108A
(ko)
|
2016-11-23 |
2021-07-09 |
하푼 테라퓨틱스, 인크. |
전립선 특이 막 항원 결합 단백질
|
|
CN110023338A
(zh)
|
2016-12-08 |
2019-07-16 |
伊莱利利公司 |
用于与抗pd-l1抗体组合的抗tim-3抗体
|
|
JOP20190133A1
(ar)
|
2016-12-08 |
2019-06-02 |
Innovent Biologics Suzhou Co Ltd |
أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1
|
|
BR112019011988A2
(pt)
|
2016-12-13 |
2019-11-05 |
Astellas Pharma Inc |
anticorpo anti-cd73 humana
|
|
WO2018115859A1
(en)
|
2016-12-20 |
2018-06-28 |
Kymab Limited |
Multispecific antibody with combination therapy for immuno-oncology
|
|
EP4001269A1
(en)
|
2016-12-22 |
2022-05-25 |
Amgen Inc. |
Benzoisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
|
|
WO2018136725A1
(en)
|
2017-01-19 |
2018-07-26 |
Harpoon Therapeutics, Inc. |
Innate immune cell inducible binding proteins and methods of use
|
|
JP7280828B2
(ja)
|
2017-01-23 |
2023-05-24 |
クレージュ メディカル カンパニー，リミテッド |
Ｂｃｍａを標的とする抗体およびその使用
|
|
US11535668B2
(en)
|
2017-02-28 |
2022-12-27 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
|
WO2018160671A1
(en)
|
2017-02-28 |
2018-09-07 |
Harpoon Therapeutics, Inc. |
Targeted checkpoint inhibitors and methods of use
|
|
KR20190134654A
(ko)
|
2017-03-09 |
2019-12-04 |
싸이톰스 테라퓨틱스, 인크. |
Cd147 항체, 활성화가능한 cd147 항체, 그리고 이를 만들고, 이용하는 방법
|
|
WO2018183366A1
(en)
|
2017-03-28 |
2018-10-04 |
Syndax Pharmaceuticals, Inc. |
Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
|
|
US20200115461A1
(en)
|
2017-05-03 |
2020-04-16 |
Harpoon Therapeutics, Inc. |
Compositions and methods for adoptive cell therapies
|
|
US20200270362A1
(en)
|
2017-05-12 |
2020-08-27 |
Harpoon Therapeutics, Inc. |
Msln targeting trispecific proteins and methods of use
|
|
IL300964A
(en)
|
2017-05-12 |
2023-04-01 |
Harpoon Therapeutics Inc |
mesothelin binding proteins
|
|
WO2018209304A1
(en)
|
2017-05-12 |
2018-11-15 |
Harpoon Therapeutics, Inc. |
Msln targeting trispecific proteins and methods of use
|
|
CA3006798A1
(en)
|
2017-06-02 |
2018-12-02 |
Pfizer Inc. |
Antibodies specific for flt3 and their uses
|
|
AU2018298676A1
(en)
|
2017-07-10 |
2019-12-19 |
Innate Pharma |
Siglec-9-neutralizing antibodies
|
|
US11447545B2
(en)
|
2017-07-10 |
2022-09-20 |
Innate Pharma |
Combination therapy using antibody to human Siglec-9 and antibody to human NKG2A for treating cancer
|
|
AU2018311503C1
(en)
|
2017-08-01 |
2023-11-30 |
Medimmune, Llc |
BCMA monoclonal antibody-drug conjugate
|
|
JP7151175B2
(ja)
|
2017-09-15 |
2022-10-12 |
日本電産株式会社 |
変速機及びアクチュエータ
|
|
PE20201183A1
(es)
|
2017-10-13 |
2020-11-03 |
Harpoon Therapeutics Inc |
Proteinas trispecificas y metodos de uso
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
US11564946B2
(en)
|
2017-11-01 |
2023-01-31 |
Juno Therapeutics, Inc. |
Methods associated with tumor burden for assessing response to a cell therapy
|
|
WO2019136305A1
(en)
|
2018-01-04 |
2019-07-11 |
Neumedicines Inc. |
Cell-based and immune checkpoint inhibitor therapies combined with il-12 for treating cancer
|
|
CA3089230A1
(en)
|
2018-03-02 |
2019-09-06 |
Cdr-Life Ag |
Trispecific antigen binding proteins
|
|
US20210269530A1
(en)
|
2018-05-14 |
2021-09-02 |
Harpoon Therapeutics, Inc. |
Conditionally activated binding protein comprising a sterically occluded target binding domain
|
|
EP3794044A4
(en)
|
2018-05-14 |
2022-02-16 |
Harpoon Therapeutics, Inc. |
DOUBLE BINDING UNIT
|
|
KR20210020903A
(ko)
|
2018-05-14 |
2021-02-24 |
하푼 테라퓨틱스, 인크. |
면역글로불린 분자의 조건부 활성화를 위한 결합 모이어티
|
|
UY38251A
(es)
|
2018-06-01 |
2019-12-31 |
Novartis Ag |
Moléculas de unión contra bcma y usos de las mismas
|
|
CA3102036A1
(en)
|
2018-06-18 |
2019-12-26 |
Anwita Biosciences, Inc. |
Cytokine fusion proteins and uses thereof
|
|
KR20250035608A
(ko)
|
2018-09-11 |
2025-03-12 |
아이테오스 벨지움 에스에이 |
A2a 억제제로서 싸이오카바메이트 유도체, 이의 약학 조성물 및 항암제와의 조합물
|
|
US20220054544A1
(en)
|
2018-09-21 |
2022-02-24 |
Harpoon Therapeutics, Inc. |
Conditionally active receptors
|
|
WO2020061482A1
(en)
|
2018-09-21 |
2020-03-26 |
Harpoon Therapeutics, Inc. |
Egfr binding proteins and methods of use
|
|
WO2020061526A1
(en)
|
2018-09-21 |
2020-03-26 |
Harpoon Therapeutics, Inc. |
Conditionally activated target-binding molecules
|
|
CA3114038A1
(en)
|
2018-09-25 |
2020-04-02 |
Harpoon Therapeutics, Inc. |
Dll3 binding proteins and methods of use
|
|
WO2020092792A2
(en)
|
2018-10-31 |
2020-05-07 |
Oncotracker, Inc. |
Method of enhancing immune-based therapy
|
|
BR112021008930A2
(pt)
|
2018-11-08 |
2021-11-03 |
Juno Therapeutics Inc |
Métodos e combinações para o tratamento e modulação de célula t
|
|
CN109593786A
(zh)
|
2019-01-09 |
2019-04-09 |
上海怡豪生物科技有限公司 |
联合EpCAM和MSLN单链抗体的双靶点CAR载体及其构建方法和在乳腺癌应用
|
|
CN114173876A
(zh)
|
2019-03-05 |
2022-03-11 |
武田药品工业有限公司 |
含有靶向肿瘤抗原的Fc区和部分的条件性活化的结合蛋白质
|
|
CN114245806A
(zh)
|
2019-05-14 |
2022-03-25 |
哈普恩治疗公司 |
EpCAM结合蛋白及使用方法
|
|
US20220306745A1
(en)
|
2019-06-13 |
2022-09-29 |
Cytomx Therapeutics, Inc. |
Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a combination therapy for the treatment of cancer
|
|
CA3144324A1
(en)
|
2019-06-24 |
2020-12-30 |
Novartis Ag |
Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen
|
|
KR102776925B1
(ko)
|
2019-06-25 |
2025-03-11 |
길리애드 사이언시즈, 인코포레이티드 |
Flt3l-fc 융합 단백질 및 사용 방법
|
|
WO2021097060A1
(en)
|
2019-11-13 |
2021-05-20 |
Harpoon Therapeutics, Inc. |
Pro immune modulating molecule comprising a clustering moiety
|
|
AU2021224851A1
(en)
|
2020-02-21 |
2022-09-15 |
Harpoon Therapeutics, Inc. |
FLT3 binding proteins and methods of use
|
|
WO2021231434A1
(en)
|
2020-05-12 |
2021-11-18 |
Harpoon Therapeutics, Inc. |
Psma targeting tritacs and methods of use
|
|
US12234291B2
(en)
|
2020-08-05 |
2025-02-25 |
Synthekine, Inc. |
IL2RB binding molecules and methods of use
|
|
US12077594B2
(en)
|
2020-08-05 |
2024-09-03 |
Synthekine, Inc. |
IL2RG binding molecules and methods of use
|
|
WO2022098909A1
(en)
|
2020-11-06 |
2022-05-12 |
Harpoon Therapeutics, Inc. |
Epcam targeting trispecific protein for treatment of cancer
|
|
EP4304728A4
(en)
|
2021-03-09 |
2025-08-20 |
Harpoon Therapeutics Inc |
COMBINATION THERAPY WITH IMMUNE CELL CONTACT PROTEINS AND IMMUNOMODULATORS
|
|
WO2022212732A1
(en)
|
2021-04-01 |
2022-10-06 |
Harpoon Therapeutics, Inc. |
Psma targeting tritacs and methods of use
|
|
WO2022256498A1
(en)
|
2021-06-03 |
2022-12-08 |
Harpoon Therapeutics, Inc. |
Msln targeting trispecific proteins and methods of use
|
|
JP2024520727A
(ja)
|
2021-06-03 |
2024-05-24 |
ハープーン セラピューティクス，インク． |
Ｂｃｍａ標的化三重特異性タンパク質およびその使用
|
|
EP4347637A4
(en)
|
2021-06-03 |
2025-04-16 |
Harpoon Therapeutics, Inc. |
DLL3 as a target for trispecific proteins and methods of use
|
|
WO2022272033A2
(en)
|
2021-06-25 |
2022-12-29 |
Harpoon Therapeutics, Inc. |
Extended-release immune cell engaging proteins and methods of treatment
|
|
EP4416185A4
(en)
|
2021-10-15 |
2025-09-03 |
Harpoon Therapeutics Inc |
CONDITIONAL ACTIVATION OF IMMUNOGLOBULIN MOLECULES
|